Sacred Reciprocity, Biocultural Conservation, and Honouring our Indigenous Ancestors with Chacruna’s Joseph Mays
Similar Posts
BIG UPDATE On The LARGEST Psychedelic Therapy Clinical Trial: CMPS’ Psilocybin-Depression Study
HUGE UPDATE: Compass Pathways, (NASDAQ: CMPS), completes the LARGEST Phase 2b psilocybin clinical study to treat treatment resistant depression (TRD).
This is the most important psychedelic therapy study that we know of because it is both the largest clinical trial testing psilocybin to date and it is also the most advanced in the clinical trial process.
In this episode we will discuss:
– The details of this trial and why it is so important;
– The big update that we have for you;
– When we can expect results;
– Where the field goes from here in the near future.
Timestamps:
0:00 – Intro
1:31 – What is Compass Pathways’ Phase2b trial and why is it important?
6:57 – The major Update on CMPS’ Clinical Trial
8:07 – Anticipated results date & what these results will mean for the psychedelic industry
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#CompassPathways #CMPS #PsychedelicTherapy
MindMed Near Term CATALYSTS & Nasdaq Debrief [MMED / MNMD]
So what happened with MindMed (MMED / MNMD) on the day on the NASDAQ uplisting? As we all know, MindMed announced on 23rd of April that the MMEDF stock will uplist on NASDAQ on April 27th under ticker MNMD. for MMED : NEO owners, the stock ticker will remain the same, adjusted to US ER.
Ever since, we all speculated on what will happen to the MindMed stock on April 27 and what will be it’s closing price? On April 26th, the stock price rose to near all time highs and a lot of retail investors thought that on the 27th, the run will continue. MindMed’s move to the Nasdaq was to increase the visibility of its stock in hopes of reaching out to a new group of retail and institutional investors.
Unfortunately, the plan didn’t go so well. While MindMed opened at the previous all time high, the stock dropped throughout the day. MindMed, (MNMD) closed today after its first day on the Nasdaq at: $4.02, down 16%,
most probably due to investors who took some profits, which was one of the scenarios in our previous video on MindMed Nasdaq Uplisting price predictions.
So in this video, I’ll share my thoughts on today’s MMED / MNMD stock events and then discuss the near time future catalysts for MindMed.
Timestamps:
0:00 – Intro
1:27 – Thoughts on MindMed (MNMD) first trading day on NASDAQ
6:05 – MindMed catalyst #1 – Atai’s IPO
7:37 – PSIL ETF coming soon
9:58 – Phase 2a results for MindMed’s Project LUCY
11:38 – Project LUCY starting Phase2b in Q4 this year
12:26 – Completion of Phase 1 Trial for Project Layla (18-MC)
13:08 – Completion of Phase 1 LSD Neutralizer Study
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
Links to Clinical trials :
https://clinicaltrials.gov/ct2/results?cond=&term=LSD&cntry=&state=&city=&dist=
https://clinicaltrials.gov/ct2/show/NCT03153579?term=LSD&draw=2&rank=5&fbclid=IwAR3fZtlvGX2UAFI0pOkFNANqVpU8ac5pLBTyfwfbd3D4v_1OW61fZLFZGkY
https://clinicaltrials.gov/ct2/show/NCT03604744?term=LSD&draw=2&rank=6&fbclid=IwAR3fZtlvGX2UAFI0pOkFNANqVpU8ac5pLBTyfwfbd3D4v_1OW61fZLFZGkY
https://mindmed.co/wp-content/uploads/2021/04/MindMed-Corporate-Presentation-4.27.2021.pdf
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedNasdaq #MindMedstock
New Players, BUY Ratings, Financial Results & MORE ( MINDMED, NUMI, CMPS, MYCO, FTRP, HAVN, DMT)
There were A LOT OF DEVELOPMENTS THIS WEEK, so strap on your seat belts and let’s dive into what happened this week with: MindMed ( MMED / MNMD / MMQ ), Compass Pathways (CMPS), NUMINUS (NUMI), Fieldtrip Health (FTRP / FTRPF), Mydecine ( MYCO / MYCOF), HAVN Labs
( HAVN / HAVLF), Novamind ( NM / NVMDF), Champignon Brands aka Braxia Scientific
(old ticker :SHRM / new ticker: BRAX / BRAXF), Nova Mentis (NOVA / NMLSF) and Small Pharma (DMT).
Timestamps:
0:00 – Intro
0:54 – MindMed’s (MMED / MNMD) Project Angie Announcement
1:47 – Compass Pathways (CMPS) Q1 Financial Results Date & Business Updates
3:16 – Analyst Coverage and Buy Ratings for CMPS
4:35 – Mydecine ( MYCO / MYCOF) 2020 Financial Results & Business Highlights
9:17 – Numinus Wellness (NUMI) Q2 Financial Results
11:25 – Field Trip Health (FTRP/ FTRPF) Opens more clinics
12:19 – Novamind ( NM / NVMDF) doubling its clinics
14:25 – Champignon Brands (SHRM /SHRMF) changing its named to Braxia Scientific (BRAX / BRAXF)
15:31 – NEW DMT company that began trading on may 6th under the name SMALL PHARMA ( DMT)
17:19 – HAVN Labs (HAVN) opens a new lab in Jamaica
17:50 – Nova Mentis launches a new clinical study using psilocybin to treat autism
Link to MindMed’s Project Angie Press release:
https://mindmed.co/news/press-release/mindmed-announces-project-angie-targeting-the-treatment-of-pain-with-psychedelics/
Link to Compass Pathways Q1 financial Results date:
https://ir.compasspathways.com/news-releases/news-release-details/compass-pathways-plc-announce-first-quarter-2021-financial
Link to Compass Pathways (CMPS) analyst ratings: https://www.marketbeat.com/stocks/NASDAQ/CMPS/price-target/
Link to Mydecine ( MYCO/ MYCOF) Full Year 2020 Financial results Plus business updates
https://www.globenewswire.com/news-release/2021/05/03/2221266/0/en/Mydecine-Reports-Full-Year-2020-Financial-Results-and-Provides-Business-Update.html
Link to Numinus (NUMI) Q2 2021 Financial Results:
https://www.newswire.ca/news-releases/numinus-wellness-q2-2021-results-highlighted-by-17-25-million-financing-mindspace-wellbeing-acquisition-and-clinical-trial-collaboration-with-maps-pbc-846735411.html
Link to Field Trip’s (FTPR / FTPRF) 7th Psychedelic-assisted therapy Clinic:
https://psilocybinalpha.com/news/field-trip-health-ltd-announces-opening-of-psychedelic-enhanced-therapy-center-in-houston-locations-of-next-5-field-trip-health-centers
Link to Novamind’s (NM / NVMDF) Ketamine Clinic article:
https://novamind.ca/2021-05-04-novamind-doubles-in-size-adds-four-new-psychedelic-mental-health-clinics/
Link to Champignon Brands ( SHRM/ SHRMF) announcing their name change to Braxia Scientific (BRAX / BRAXF):
https://thedeepdive.ca/champignon-brands-to-change-name-to-braxia-scientific/
Link to Small Pharma ( DMT):
https://psilocybinalpha.com/news/small-pharma-completes-reverse-take-over-transaction
Link to Havn’s (HAVN / HAVLF) Jamaica lab:
https://www.psychedelicfinance.com/articles/havn-labs-jamaica-facility-now-fully-operational
Link to Nova Mentis launching a clinical study to learn more about Autism:
https://psilocybinalpha.com/news/nova-mentis-launches-autism-clinical-study
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
editing by: @themyaholy
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #Numi #CMPS
Sena Maria On The Benefits of Microdosing
In this episode, Sena Maria gives us an overview of her Microdosing Activation program and explains some of the benefits of microdosing.
MindMed (MMED) Cluster Headaches LSD Trials Update (and response to criticisms)
Hey guys! Here is an Update and response to our easily most controversial video “MindMed (MMED) Suicide Headaches trial VANISHES from Website ( What Happened?)”. We got a response from MindMed while also receiving some backlash from the MindMed investors community that will be addressed. Hope you guys find some value in this video. I appreciate you guys. LOOVE all comments and criticisms. Caio!
P.S. S/O to Magic Shrooms who also contributed by commenting that he “received a reply from MMED concerning about the cluster headaches trial. they said that there has been no changes in regard to their on-going trial using LSD for suicide headaches!”
Just to let you know, we temporarily (perhaps permanently?) have removed the first video, while we discuss how to move forward.
Subscribe to our channel to get the latest updates on Psychedelic Stocks. Follow the MMED stock and other companies like it.
Let us know in the comments what you think about the new way we edited our video? Do you like it more than how we edited them previously?
🎵 Music: www.bensound.com
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #mmed #mindmedstock #psychedelicstocks #mmedf
Interview With Nick Levich
Psychedelic Passage’s Co-Founder and Facilitator, Nick Levich, talks about the function, purpose and importance of a trip sitter during a psychedelic experience.